Solid Biosciences

JPMorgan Upgrades Solid Biosciences Stock, Sees Growth Potential

JPMorgan upgraded Solid Biosciences stock, a biotechnology company that acquired UF startup AavantiBio, from Neutral to Overweight, and increased the price target to $15.00 from the previous $10.00. The firm's decision reflects a positive outlook on the company's prospects, particularly with upcoming developments expected in the fourth quarter.

Solid Biosciences Joins the Russell 3000® Index

Solid Biosciences Inc., a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases that acquired UF startup AavantiBio, announced it has been added to the broad-market Russell 3000® Index as part of the annual reconstitution, effective July 1st, 2024.